Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals Abstract #1303

Introduction: Lanreotide depot (LAN) was recently approved by the FDA to treat mGEP-NETs to improve progression-free survival.
Aim(s): To determine real-world costs of two therapies for mGEP-NETs.
Materials and methods: A hypothetical cohort of 500 GEP-NET patients is considered the treated population in the model, with the proportion treated with an SSA estimated using published epidemiologic data. Drug acquisition, preparation, dosing and administration costs are included based on a national pricing database and published literature. Published estimates of real-world dosing of octreotide (OCT) are utilized as a model assumption. As LAN was approved recently, real-world dosing was unavailable and the model assumed labeled dosing.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba

To read results and conclusion, please login ...

Further abstracts you may be interested in

#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
#1708 STREET - Somatostatin Treatment Experience Trial
Introduction: Somatostatin analogs (SSA) delay progress and decrease symptoms in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). It is not known whether patients’ experiences of injection treatment differ between different SSAs.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ass. prof. Martin Almquist
#2160 A Comparison of Retrospective Database Analysis with Chart Review in Patients Receiving Somatostatin Analog (SSA) in Neuroendocrine Tumors (NETs)
Introduction: SSAs are recommended for the treatment of locoregional/metastatic NET.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: David Ray
Authors: Klink A, Feinberg B, Yu H T, Ray D, ...
#1504 Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs
Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba
Keywords: Lung NETs, lanreotide
#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan